Skip to main content

Table 1 Patient and tumor characteristics

From: Surgical treatment for locally advanced lower third rectal cancer after neoadjuvent chemoradiation with capecitabine: prospective phase II trial

Age:

 

Median

65

Range

36–73

Gender, No. (%):

 

Male

28 (65.1)

Female

15 (34.9)

Clinical tumor stage, No. (%):

 

T3N0

5 (11.6)

T3N1

15 (34.9)

T4N0

13 (30.2)

T4N1

10 (23.3)

Performance status, No. (%)

 

0

33 (76.7)

1

10 (23.3)

Distance from anal verge:

 

Median (cm)

5.5

0 – <5 cm, No. (%)

16 (37.2)

5 – ≤ 7 cm, No. (%)

27 (62.8)